HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) and maintains an $80 price target.

April 17, 2024 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Celldex Therapeutics maintains a Buy rating and an $80 price target from HC Wainwright & Co., indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of an $80 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong conviction in Celldex Therapeutics' potential for growth and success. This positive analyst outlook can influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100